Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
81.60
+1.08 (1.35%)
Jun 8, 2026, 11:06 AM EDT - Market open
Dianthus Therapeutics Revenue
Dianthus Therapeutics had revenue of $463.00K in the quarter ending March 31, 2026, a decrease of -60.19%. This brings the company's revenue in the last twelve months to $1.34M, down -79.52% year-over-year. In the year 2025, Dianthus Therapeutics had annual revenue of $2.04M, down -67.35%.
Revenue (ttm)
$1.34M
Revenue Growth
-79.52%
P/S Ratio
3,294.30
Revenue / Employee
$14,522
Employees
92
Market Cap
4.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | -4.20M | -67.35% |
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 907.29M |
| Catalyst Pharmaceuticals | 596.96M |
| Travere Therapeutics | 536.20M |
| Ligand Pharmaceuticals | 274.48M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 5.07M |
| CRISPR Therapeutics AG | 4.10M |
DNTH News
- 4 days ago - Dianthus Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Dianthus Therapeutics to Participate in Two Investor Conferences - GlobeNewsWire
- 19 days ago - Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - GlobeNewsWire
- 27 days ago - Dianthus price target lowered to $120 from $122 at Evercore ISI - TheFly
- 4 weeks ago - Dianthus price target raised to $125 from $123 at Raymond James - TheFly
- 4 weeks ago - LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis - GlobeNewsWire
- 4 weeks ago - Dianthus reports Q1 EPS (85c), consensus ($1.10) - TheFly